



CORRECTION

Correction: Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma—experience of the BriTROc consortium


T Goranova¹, D Ennis², A M Piskorz¹, G Macintyre¹, L A Lewsley³, J Stobo³, C Wilson³, D Kay⁴, R M Glasspool⁵, M Lockley^{6,7}, E Brockbank⁶, A Montes⁸, A Walther⁹, S Sundar¹⁰, R Edmondson¹¹, G D Hall¹², A Clamp¹³, C Gourley¹⁴, M Hall¹⁵, C Fotopoulou¹⁶, H Gabra¹⁶, S Freeman¹⁷, L Moore¹⁷, M Jimenez-Linan¹⁷, J Paul³, J D Brenton^{1,17} and I A McNeish^{2,5} on behalf of the BriTROc investigators

British Journal of Cancer (2019) 120:868; <https://doi.org/10.1038/s41416-019-0433-6>

Correction to: *British Journal of Cancer* **116**,1294–1301; <https://doi.org/10.1038/bjc.2017.86>; published online 30 March 2017

This article was originally published under a CC BY NC SA License, but has now been made available under a CC BY 4.0 License.

appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give

© The Author(s) 2019

¹Cancer Research UK Cambridge Institute, Cambridge CB2 0RE, UK; ²Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK; ³Cancer Research UK Clinical Trials Unit, Glasgow G12 0YN, UK; ⁴Department of Radiology, Gartnavel General Hospital, Glasgow G12 0YN, UK; ⁵Beatson West of Scotland Cancer Centre, Glasgow G12 0YN, UK; ⁶Barts Cancer Institute, London EC1M 6BQ, UK; ⁷University College Hospital, London WC1E 6BD, UK; ⁸Guy's Hospital, London SE1 9RT, UK; ⁹Bristol Haematology and Oncology Centre, Bristol BS2 8ED, UK; ¹⁰City Hospital, Birmingham B18 7QH, UK; ¹¹St Mary's Hospital, Manchester M13 9WL, UK; ¹²St James Hospital, Leeds LS9 7TF, UK; ¹³The Christie Hospital, Manchester M20 4BX, UK; ¹⁴Edinburgh Cancer Research Centre, Edinburgh EH4 2XR, UK; ¹⁵Mount Vernon Cancer Centre, Northwood HA6 2RN, UK; ¹⁶Imperial College, London W12 0HS, UK and ¹⁷Addenbrooke's Hospital, Cambridge CB2 0QQ, UK

Correspondence: J D Brenton (james.brenton@cruk.cam.ac.uk) or I A McNeish (iain.mcneish@glasgow.ac.uk)

Published online: 13 March 2019